Skip to main content
Erschienen in: Journal of Neurology 11/2019

17.08.2019 | Original Communication

Thalassemia and Moyamoya syndrome: unfurling an intriguing association

verfasst von: Shambaditya Das, Souvik Dubey, Mrinal Acharya, Subhankar Chatterjee, Durjoy Lahiri, Goutam Das, Biman Kanti Ray, Markus Kraemer

Erschienen in: Journal of Neurology | Ausgabe 11/2019

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Moyamoya angiopathy (MMA) is a rare cerebrovascular disease with progressive bilateral narrowing of intracranial parts of the internal carotid artery and proximal parts of the anterior and middle cerebral artery resulting in recurrent hemodynamic ischemic attacks, strokes and hemorrhages. If associated with other diseases, it is called Moyamoya syndrome (MMS). Until now, MMS has rarely been described with thalassemia.

Methods

Of the 75 cases of MMA collected in our Indian center in the last 3 years, 4 new patients with the rare cooccurence of thalassemia and MMS were found. Thalassemia cases were confirmed by hemoglobin electrophoresis and MMA was diagnosed on the basis of MR angiography. Other known secondary causes of MMA were ruled out by relevant investigations. Thirteen previously reported cases of thalassemia and MMA were retrieved by literature search in PubMed and Google Scholar using the keywords “Moyamoya” AND “thalassemia”. Subsequently all the data were analyzed and compared by using descriptive statistics.

Results

Analysis of our 4 cases and those 13 found in the literature showed early childhood diagnosis of thalassemia and in most cases later manifestation of MMS in the age of 14.5 + 10.72 years (mean + SD) in our cases and with 10.97 + 6.47 years in previous cases. While 9 out of the former 13 and 3 of our 4 cases showed obvious infarcts in brain imaging, 1 case with HbE-β-thalassemia presented with intracerebral hemorrhage. Hemiplegia/hemiparesis was present among all of our 4 cases, while it was present in 69.23% cases of the previous 13 reports. Neither transfusion dependence nor the history of splenectomy was found to be associated with MMA development.

Conclusion

These four new cases of MMS in thalassemia enlarged our knowledge about MMS in patients with thalassemia. MMS is a relevant complication in patients with thalassemia and early detection is essential to avoid disability.
Literatur
1.
Zurück zum Zitat Scott RM, Smith ER (2009) Moyamoya disease and moyamoya syndrome. N Engl J Med 360:1226–1237PubMed Scott RM, Smith ER (2009) Moyamoya disease and moyamoya syndrome. N Engl J Med 360:1226–1237PubMed
2.
Zurück zum Zitat Fujimura M, Tominaga T (2015) Diagnosis of moyamoya disease: international standard and regional differences. Neurol Med Chir (Tokyo) 55:189–193 Fujimura M, Tominaga T (2015) Diagnosis of moyamoya disease: international standard and regional differences. Neurol Med Chir (Tokyo) 55:189–193
3.
Zurück zum Zitat Zhao M, Zhang D, Wang S, Zhang Y, Wang R, Deng X et al (2018) Posterior circulation involvement in pediatric and adult patients with moyamoya disease: a single center experience in 574 patients. Acta Neurol Belg 118:227–233PubMed Zhao M, Zhang D, Wang S, Zhang Y, Wang R, Deng X et al (2018) Posterior circulation involvement in pediatric and adult patients with moyamoya disease: a single center experience in 574 patients. Acta Neurol Belg 118:227–233PubMed
4.
Zurück zum Zitat Dobson SR, Holden KR, Nietert PJ, Cure JK, Laver JH, Disco D et al (2002) Moyamoya syndrome in childhood sickle cell disease: a predictive factor for recurrent cerebrovascular events. Blood 99:3144–3150PubMed Dobson SR, Holden KR, Nietert PJ, Cure JK, Laver JH, Disco D et al (2002) Moyamoya syndrome in childhood sickle cell disease: a predictive factor for recurrent cerebrovascular events. Blood 99:3144–3150PubMed
5.
Zurück zum Zitat Mukherjee A (1995) Moyamoya disease and beta-thalassemia. J Assoc Physicians India 43:710–711PubMed Mukherjee A (1995) Moyamoya disease and beta-thalassemia. J Assoc Physicians India 43:710–711PubMed
6.
Zurück zum Zitat Sanefuji M, Ohga S, Kira R, Yoshiura T, Torisu H, Hara T (2006) Moyamoya syndrome in a splenectomized patient with beta-thalassemia intermedia. J Child Neurol 21:75–77PubMed Sanefuji M, Ohga S, Kira R, Yoshiura T, Torisu H, Hara T (2006) Moyamoya syndrome in a splenectomized patient with beta-thalassemia intermedia. J Child Neurol 21:75–77PubMed
7.
Zurück zum Zitat Marden FA, Putman CM, Grant JM, Greenberg J (2008) Moyamoya disease associated with hemoglobin Fairfax and beta-thalassemia. Pediatr Neurol 38:130–132PubMed Marden FA, Putman CM, Grant JM, Greenberg J (2008) Moyamoya disease associated with hemoglobin Fairfax and beta-thalassemia. Pediatr Neurol 38:130–132PubMed
8.
Zurück zum Zitat Parker TM, Ward LM, Johnston DL, Ventureya E, Klaassen RJ (2009) A case of Moyamoya syndrome and hemoglobin E/beta-thalassemia. Pediatr Blood Cancer 52:422–424PubMed Parker TM, Ward LM, Johnston DL, Ventureya E, Klaassen RJ (2009) A case of Moyamoya syndrome and hemoglobin E/beta-thalassemia. Pediatr Blood Cancer 52:422–424PubMed
9.
Zurück zum Zitat Göksel BK, Ozdogu H, Yildirim T, Oğuzkurt L, Asma S (2010) Beta-thalassemia intermedia associated with moyamoya syndrome. J Clin Neurosci 17:919–920PubMed Göksel BK, Ozdogu H, Yildirim T, Oğuzkurt L, Asma S (2010) Beta-thalassemia intermedia associated with moyamoya syndrome. J Clin Neurosci 17:919–920PubMed
10.
Zurück zum Zitat Oberoi S, Bansal D, Singh P, Marwaha RK (2010) Stroke in a young boy with β-thalassemia intermedia secondary to moyamoya syndrome. J Pediatr Hematol Oncol 32:568–570PubMed Oberoi S, Bansal D, Singh P, Marwaha RK (2010) Stroke in a young boy with β-thalassemia intermedia secondary to moyamoya syndrome. J Pediatr Hematol Oncol 32:568–570PubMed
11.
Zurück zum Zitat Ray A, Rodriguez N (2011) Cerebral infarction in the setting of moyamoya in a pediatric patient with sickle β+-thalassemia. Pediatr Hematol Oncol 28:535–537PubMed Ray A, Rodriguez N (2011) Cerebral infarction in the setting of moyamoya in a pediatric patient with sickle β+-thalassemia. Pediatr Hematol Oncol 28:535–537PubMed
12.
Zurück zum Zitat Inati A, Tourjuman O, Bizri D, Dhayni R, Abbas HA, Tfaili H et al (2013) A rare case of Moyamoya syndrome in a β-thalassemia major patient. Blood Cells Mol Dis 51:149–150PubMed Inati A, Tourjuman O, Bizri D, Dhayni R, Abbas HA, Tfaili H et al (2013) A rare case of Moyamoya syndrome in a β-thalassemia major patient. Blood Cells Mol Dis 51:149–150PubMed
13.
Zurück zum Zitat Nadkarni J, Pal P, Dwivedi R, Singh A (2014) Vasculopathy in beta thalassemia intermedia: a rare case report. Sch J App Med Sci 2(1C):345–347 Nadkarni J, Pal P, Dwivedi R, Singh A (2014) Vasculopathy in beta thalassemia intermedia: a rare case report. Sch J App Med Sci 2(1C):345–347
14.
Zurück zum Zitat El Beltagi AH, El-Sheikh A, El-Saif R, Norbash A (2014) Ivy sign in mildly symptomatic β-thalassemia intermedia, with development of moyamoya disease. Neuroradiol J 27:23–28PubMedPubMedCentral El Beltagi AH, El-Sheikh A, El-Saif R, Norbash A (2014) Ivy sign in mildly symptomatic β-thalassemia intermedia, with development of moyamoya disease. Neuroradiol J 27:23–28PubMedPubMedCentral
15.
Zurück zum Zitat Sarkar KN, Deoghuria D, Sarkar M, Sarkar S (2016) Moyamoya syndrome in a HbE beta thalassemic child presenting with hemiplegia in rural West Bengal. IOSR J Med Dent Sci 15:113–118 Sarkar KN, Deoghuria D, Sarkar M, Sarkar S (2016) Moyamoya syndrome in a HbE beta thalassemic child presenting with hemiplegia in rural West Bengal. IOSR J Med Dent Sci 15:113–118
17.
Zurück zum Zitat Doctor PN, Choudhari A, Verma M, Merchant RH (2018) Moyamoya syndrome in hemoglobin E-beta thalassemia: A rare presentation and association. J Postgrad Med 64:240–242PubMedPubMedCentral Doctor PN, Choudhari A, Verma M, Merchant RH (2018) Moyamoya syndrome in hemoglobin E-beta thalassemia: A rare presentation and association. J Postgrad Med 64:240–242PubMedPubMedCentral
18.
Zurück zum Zitat Brockmann K, Stolpe S, Fels C, Khan N, Kulozik AE, Pekrun A (2005) Moyamoya syndrome associated with hemolytic anemia due to Hb Alesha. J Pediatr Hematol Oncol 27:436–440PubMed Brockmann K, Stolpe S, Fels C, Khan N, Kulozik AE, Pekrun A (2005) Moyamoya syndrome associated with hemolytic anemia due to Hb Alesha. J Pediatr Hematol Oncol 27:436–440PubMed
19.
Zurück zum Zitat Haque A, Quint DJ, Castle VP, Leber SM (2015) Another rare unstable hemoglobinopathy: hemoglobin Casper/Southampton associated with Moyamoya disease. Cerebrovasc Dis Extra 5:52–54PubMedPubMedCentral Haque A, Quint DJ, Castle VP, Leber SM (2015) Another rare unstable hemoglobinopathy: hemoglobin Casper/Southampton associated with Moyamoya disease. Cerebrovasc Dis Extra 5:52–54PubMedPubMedCentral
20.
Zurück zum Zitat Shulman JG, Snider S, Vaitkevicius H, Babikian VL, Patel NJ (2017) Direct visualization of arterial emboli in Moyamoya syndrome. Front Neurol 8:425PubMedPubMedCentral Shulman JG, Snider S, Vaitkevicius H, Babikian VL, Patel NJ (2017) Direct visualization of arterial emboli in Moyamoya syndrome. Front Neurol 8:425PubMedPubMedCentral
21.
Zurück zum Zitat Kraemer M, Berlit P, Diesner F, Khan N (2012) What is the expert’s option on antiplatelet therapy in moyamoya disease? Results of a worldwide Survey. Eur J Neurol 19:163–167PubMed Kraemer M, Berlit P, Diesner F, Khan N (2012) What is the expert’s option on antiplatelet therapy in moyamoya disease? Results of a worldwide Survey. Eur J Neurol 19:163–167PubMed
22.
23.
Zurück zum Zitat Cappellini MD, Poggiali E, Taher AT, Musallam KM (2012) Hypercoagulability in β-thalassemia: a status quo. Expert Rev Hematol 5:505–511PubMed Cappellini MD, Poggiali E, Taher AT, Musallam KM (2012) Hypercoagulability in β-thalassemia: a status quo. Expert Rev Hematol 5:505–511PubMed
24.
Zurück zum Zitat Cappellini MD, Musallam KM, Poggiali E, Taher AT (2012) Hypercoagulability in non-transfusion-dependent thalassemia. Blood Rev 26(Suppl 1):S20–S23PubMed Cappellini MD, Musallam KM, Poggiali E, Taher AT (2012) Hypercoagulability in non-transfusion-dependent thalassemia. Blood Rev 26(Suppl 1):S20–S23PubMed
25.
Zurück zum Zitat Taher AT, Otrock ZK, Uthman I, Cappellini MD (2008) Thalassemia and hypercoagulability. Blood Rev 22:283–292PubMed Taher AT, Otrock ZK, Uthman I, Cappellini MD (2008) Thalassemia and hypercoagulability. Blood Rev 22:283–292PubMed
26.
Zurück zum Zitat Taher AT, Musallam KM, Karimi M, El-Beshlawy A, Belhoul K, Daar S et al (2010) Splenectomy and thrombosis: the case of thalassemia intermedia. J Thromb Haemost 8:2152–2158PubMed Taher AT, Musallam KM, Karimi M, El-Beshlawy A, Belhoul K, Daar S et al (2010) Splenectomy and thrombosis: the case of thalassemia intermedia. J Thromb Haemost 8:2152–2158PubMed
27.
Zurück zum Zitat Eldor A, Rachmilewitz EA (2002) The hypercoagulable state in thalassemia. Blood 99:36–43PubMed Eldor A, Rachmilewitz EA (2002) The hypercoagulable state in thalassemia. Blood 99:36–43PubMed
28.
Zurück zum Zitat Taher AT, Musallam KM, Karimi M, El-Beshlawy A, Belhoul K, Daar S et al (2010) Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. Blood 115:1886–1892PubMed Taher AT, Musallam KM, Karimi M, El-Beshlawy A, Belhoul K, Daar S et al (2010) Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. Blood 115:1886–1892PubMed
29.
Zurück zum Zitat Borenstain-Ben Yashar V, Barenholz Y, Hy-Am E, Rachmilewitz EA, Eldor A (1993) Phosphatidylserine in the outer leaflet of red blood cells from beta-thalassemia patients may explain the chronic hypercoagulable state and thrombotic episodes. Am J Hematol 44:63–65PubMed Borenstain-Ben Yashar V, Barenholz Y, Hy-Am E, Rachmilewitz EA, Eldor A (1993) Phosphatidylserine in the outer leaflet of red blood cells from beta-thalassemia patients may explain the chronic hypercoagulable state and thrombotic episodes. Am J Hematol 44:63–65PubMed
30.
Zurück zum Zitat Ruf A, Pick M, Deutsch V, Patscheke H, Goldfarb A, Rachmilewitz EA et al (1997) In-vivo platelet activation correlates with red cell anionic phospholipid exposure in patients with beta-thalassaemia major. Br J Haematol 98:51–56PubMed Ruf A, Pick M, Deutsch V, Patscheke H, Goldfarb A, Rachmilewitz EA et al (1997) In-vivo platelet activation correlates with red cell anionic phospholipid exposure in patients with beta-thalassaemia major. Br J Haematol 98:51–56PubMed
31.
Zurück zum Zitat Mannucci PM (2010) Red cells playing as activated platelets in thalassemia intermedia. J Thromb Haemost 8:2149–2151PubMed Mannucci PM (2010) Red cells playing as activated platelets in thalassemia intermedia. J Thromb Haemost 8:2149–2151PubMed
32.
Zurück zum Zitat Cappellini MD, Robbiolo L, Bottasso BM, Coppola R, Fiorelli G, Mannucci AP (2000) Venous thromboembolism and hypercoagulability in splenectomized patients with thalassaemia intermedia. Br J Haematol 111:467–473PubMed Cappellini MD, Robbiolo L, Bottasso BM, Coppola R, Fiorelli G, Mannucci AP (2000) Venous thromboembolism and hypercoagulability in splenectomized patients with thalassaemia intermedia. Br J Haematol 111:467–473PubMed
33.
Zurück zum Zitat Goldschmidt N, Spectre G, Brill A, Zelig O, Goldfarb A, Rachmilewitz E et al (2008) Increased platelet adhesion under flow conditions is induced by both thalassemic platelets and red blood cells. Thromb Haemost 100:864–870PubMed Goldschmidt N, Spectre G, Brill A, Zelig O, Goldfarb A, Rachmilewitz E et al (2008) Increased platelet adhesion under flow conditions is induced by both thalassemic platelets and red blood cells. Thromb Haemost 100:864–870PubMed
34.
Zurück zum Zitat Del Principe D, Menichelli A, Di Giulio S, De Matteis W, Cianciulli P, Papa G (1993) PADGEM/GMP-140 expression on platelet membranes from homozygous beta thalassaemic patients. Br J Haematol 84:111–117PubMed Del Principe D, Menichelli A, Di Giulio S, De Matteis W, Cianciulli P, Papa G (1993) PADGEM/GMP-140 expression on platelet membranes from homozygous beta thalassaemic patients. Br J Haematol 84:111–117PubMed
35.
Zurück zum Zitat Tripatara A, Jetsrisuparb A, Teeratakulpisarn J, Kuaha K (2007) Hemostatic alterations in splenectomized and non-splenectomized patients with beta-thalassemia/hemoglobin E disease. Thromb Res 120:805–810PubMed Tripatara A, Jetsrisuparb A, Teeratakulpisarn J, Kuaha K (2007) Hemostatic alterations in splenectomized and non-splenectomized patients with beta-thalassemia/hemoglobin E disease. Thromb Res 120:805–810PubMed
36.
Zurück zum Zitat Al-Hawsawi ZM, Al-Zaid MA, Barnawi AI, Yassine SM (2015) Fanconi anemia associated with moyamoya disease in Saudi Arabia. Saudi Med J 36:233–235PubMedPubMedCentral Al-Hawsawi ZM, Al-Zaid MA, Barnawi AI, Yassine SM (2015) Fanconi anemia associated with moyamoya disease in Saudi Arabia. Saudi Med J 36:233–235PubMedPubMedCentral
37.
Zurück zum Zitat Gait-Carr E, Connolly DJ, King D (2017) Moyamoya syndrome associated with hereditary spherocytosis: an emerging clinical entity. J Pediatr Hematol Oncol 39:233–234PubMed Gait-Carr E, Connolly DJ, King D (2017) Moyamoya syndrome associated with hereditary spherocytosis: an emerging clinical entity. J Pediatr Hematol Oncol 39:233–234PubMed
38.
Zurück zum Zitat Meena SS, Ramkumar TV, Sharma S, Aneja S, Kumar A (2012) Moyamoya syndrome associated with severe iron deficiency anemia in a young child. Pediatr Hematol Oncol 29:368–371PubMed Meena SS, Ramkumar TV, Sharma S, Aneja S, Kumar A (2012) Moyamoya syndrome associated with severe iron deficiency anemia in a young child. Pediatr Hematol Oncol 29:368–371PubMed
39.
Zurück zum Zitat Butrum MW, Williams LS, Golomb MR (2003) A child with Diamond-Blackfan anemia, methylenetetrahydrofolate reductase mutation, and perinatal stroke. J Child Neurol 18:800–802PubMed Butrum MW, Williams LS, Golomb MR (2003) A child with Diamond-Blackfan anemia, methylenetetrahydrofolate reductase mutation, and perinatal stroke. J Child Neurol 18:800–802PubMed
40.
Zurück zum Zitat Cheng ZJ, Shen YY, Warsame IM, Dai TM, Tu JL (2018) Moyamoya syndrome caused by paroxysmal nocturnal hemoglobinuria. Chin Med J (Engl) 131:2874–2876 Cheng ZJ, Shen YY, Warsame IM, Dai TM, Tu JL (2018) Moyamoya syndrome caused by paroxysmal nocturnal hemoglobinuria. Chin Med J (Engl) 131:2874–2876
41.
Zurück zum Zitat Bersano A, Guey S, Bedini G, Nava S, Hervé D, Vajkoczy P, European Moyamoya Disease Initiative et al (2016) Research progresses in understanding the pathophysiology of Moyamoya disease. Cerebrovasc Dis 41:105–118PubMed Bersano A, Guey S, Bedini G, Nava S, Hervé D, Vajkoczy P, European Moyamoya Disease Initiative et al (2016) Research progresses in understanding the pathophysiology of Moyamoya disease. Cerebrovasc Dis 41:105–118PubMed
42.
Zurück zum Zitat Santoro C, Giugliano T, Kraemer M, Torella A, Schwitalla JC, Cirillo M et al (2018) Whole exome sequencing identifies MRVI1 as a susceptibility gene for moyamoya syndrome in neurofibromatosis type 1. PLoS ONE 13:e0200446PubMedPubMedCentral Santoro C, Giugliano T, Kraemer M, Torella A, Schwitalla JC, Cirillo M et al (2018) Whole exome sequencing identifies MRVI1 as a susceptibility gene for moyamoya syndrome in neurofibromatosis type 1. PLoS ONE 13:e0200446PubMedPubMedCentral
43.
Zurück zum Zitat Grangeon L, Guey S, Schwitalla JC, Bergametti F, Arnould M, Corpechot M (2019) Clinical and molecular features of five European multigenerational families with Moyamoya angiopathy. Stroke 50:789–796PubMed Grangeon L, Guey S, Schwitalla JC, Bergametti F, Arnould M, Corpechot M (2019) Clinical and molecular features of five European multigenerational families with Moyamoya angiopathy. Stroke 50:789–796PubMed
44.
Zurück zum Zitat Akinsheye I, Klings ES (2010) Sickle cell anemia and vascular dysfunction: the nitric oxide connection. J Cell Physiol 224:620–625PubMed Akinsheye I, Klings ES (2010) Sickle cell anemia and vascular dysfunction: the nitric oxide connection. J Cell Physiol 224:620–625PubMed
45.
Zurück zum Zitat Wood KC, Granger DN (2007) Sickle cell disease: role of reactive oxygen and nitrogen metabolites. Clin Exp Pharmacol Physiol 34:926–932PubMed Wood KC, Granger DN (2007) Sickle cell disease: role of reactive oxygen and nitrogen metabolites. Clin Exp Pharmacol Physiol 34:926–932PubMed
46.
Zurück zum Zitat Hirsch RE, Sibmooh N, Fucharoen S, Friedman JM (2017) HbE/β-thalassemia and oxidative stress: the key to pathophysiological mechanisms and novel therapeutics. Antioxid Redox Signal 26:794–813PubMedPubMedCentral Hirsch RE, Sibmooh N, Fucharoen S, Friedman JM (2017) HbE/β-thalassemia and oxidative stress: the key to pathophysiological mechanisms and novel therapeutics. Antioxid Redox Signal 26:794–813PubMedPubMedCentral
47.
Zurück zum Zitat Chamchoi A, Srihirun S, Paiboonsukwong K, Sriwantana T, Sathavorasmith P, Pattanapanyasat K et al (2018) Decreased nitrite reductase activity of deoxyhemoglobin correlates with platelet activation in hemoglobin E/ß-thalassemia subjects. PLoS ONE 13:e0203955PubMedPubMedCentral Chamchoi A, Srihirun S, Paiboonsukwong K, Sriwantana T, Sathavorasmith P, Pattanapanyasat K et al (2018) Decreased nitrite reductase activity of deoxyhemoglobin correlates with platelet activation in hemoglobin E/ß-thalassemia subjects. PLoS ONE 13:e0203955PubMedPubMedCentral
48.
Zurück zum Zitat Hervé D, Philippi A, Belbouab R, Zerah M, Chabrier S, Collardeau-Frachon S et al (2014) Loss of α1β1 soluble guanylate cyclase, the major nitric oxide receptor, leads to moyamoya and achalasia. Am J Hum Genet 94:385–394PubMedPubMedCentral Hervé D, Philippi A, Belbouab R, Zerah M, Chabrier S, Collardeau-Frachon S et al (2014) Loss of α1β1 soluble guanylate cyclase, the major nitric oxide receptor, leads to moyamoya and achalasia. Am J Hum Genet 94:385–394PubMedPubMedCentral
49.
Zurück zum Zitat Crary SE, Buchanan GR (2009) Vascular complications after splenectomy for hematologic disorders. Blood 114:2861–2868PubMedPubMedCentral Crary SE, Buchanan GR (2009) Vascular complications after splenectomy for hematologic disorders. Blood 114:2861–2868PubMedPubMedCentral
50.
Zurück zum Zitat Bader-Meunier B, Verlhac S, Elmaleh-Bergès M, Ithier G, Sellami F, Faid S et al (2009) Effect of transfusion therapy on cerebral vasculopathy in children with sickle-cell anemia. Haematologica 94:123–126PubMed Bader-Meunier B, Verlhac S, Elmaleh-Bergès M, Ithier G, Sellami F, Faid S et al (2009) Effect of transfusion therapy on cerebral vasculopathy in children with sickle-cell anemia. Haematologica 94:123–126PubMed
51.
Zurück zum Zitat Schlenz AM, Antonucci MU, Cafiero R, Burkett NS, Kanter J (2015) Moyamoya disease predicts progression of cerebral vasculopathy in patients with sickle cell disease despite chronic transfusion therapy. Blood 126:2071 Schlenz AM, Antonucci MU, Cafiero R, Burkett NS, Kanter J (2015) Moyamoya disease predicts progression of cerebral vasculopathy in patients with sickle cell disease despite chronic transfusion therapy. Blood 126:2071
53.
Zurück zum Zitat Matsushige T, Kraemer M, Sato T, Berlit P, Forsting M, Ladd ME et al (2018) Visualization and classification of deeply seated collateral networks in Moyamoya angiopathy with 7T MRI. Am J Neuroradiol 39:1248–1254PubMed Matsushige T, Kraemer M, Sato T, Berlit P, Forsting M, Ladd ME et al (2018) Visualization and classification of deeply seated collateral networks in Moyamoya angiopathy with 7T MRI. Am J Neuroradiol 39:1248–1254PubMed
54.
Zurück zum Zitat Kraemer M, Karakaya R, Matsushige T, Graf J, Albrecht P, Hartung HP et al (2018) Efficacy of STA-MCA bypass surgery in moyamoya angiopathy: long-term follow-up of the Caucasian Krupp Hospital cohort with 81 procedures. J Neurol 265:2425–2433PubMed Kraemer M, Karakaya R, Matsushige T, Graf J, Albrecht P, Hartung HP et al (2018) Efficacy of STA-MCA bypass surgery in moyamoya angiopathy: long-term follow-up of the Caucasian Krupp Hospital cohort with 81 procedures. J Neurol 265:2425–2433PubMed
Metadaten
Titel
Thalassemia and Moyamoya syndrome: unfurling an intriguing association
verfasst von
Shambaditya Das
Souvik Dubey
Mrinal Acharya
Subhankar Chatterjee
Durjoy Lahiri
Goutam Das
Biman Kanti Ray
Markus Kraemer
Publikationsdatum
17.08.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Neurology / Ausgabe 11/2019
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-019-09497-5

Weitere Artikel der Ausgabe 11/2019

Journal of Neurology 11/2019 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.